Primary Objective:To preliminarily evaluate the efficacy of GLPG0259 compared with placebo in terms of the proportion of subjects achieving ACR20 at Week 12 (Visit [V]7).Secondary Objectives:•To evaluate the efficacy of GLPG0259 compared with…
ID
Source
Brief title
Condition
- Other condition
- Autoimmune disorders
Synonym
Health condition
chronische gewrichtsaandoening
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Primary: The primary efficacy endpoint will be the number and percentage of
subjects in each GLPG0259 dose group and placebo group achieving an American
College of Rheumatology (ACR)20 (ACR20 response rate) at Week 12 (Visit [V] 7).
Secondary outcome
Secondary: The secondary efficacy endpoints will be:
• ACR20 response rate at Weeks 1, 2, 4, and 8 (V3, 4, 5, and 6);
• Time from randomization to ACR20 response;
• Number and percentage of subjects achieving ACR50 (ACR50 response rate) at
Weeks 1, 2, 4, 8, and 12 (V3, 4, 5, 6, and 7);
• Number and percentage of subjects achieving ACR70 (ACR70 response rate) at
Weeks 1, 2, 4, 8, and 12 (V3, 4, 5, 6, and 7);
• ACR-N response at Weeks 1, 2, 4, 8, and 12 (V3, 4, 5, 6, and 7);
• Change from baseline in Disease Activity Score 28 (DAS28) at Weeks 1, 2, 4,
8, and 12 (V3, 4, 5, 6, and 7); and
• Change from baseline in the core components of the ACR response and DAS28 at
Weeks 1, 2, 4, 8, and 12 (V3, 4, 5, 6, and 7).
The secondary safety endpoints will include:
• Incidence and severity of adverse events (AEs);
• Vital signs (supine heart rate and blood pressure [systolic and diastolic]);
• 12-lead electrocardiogram (ECG); and
• Clinical laboratory tests (hematology, serum chemistry, coagulation, and
urinalysis).
The secondary pharmacokinetic (PK) endpoints will include:
• Area under the curve (AUC);
• Average plasma concentration (Cave);
• Trough plasma concentration (Ctrough); and
• Terminal half life (t1/2,z).
Background summary
Despite the recent advances in RA treatment, there is still a need for orally
administered novel therapies that can effectively reduce the signs and symptoms
of the disease. GLPG0259 is a small molecule for oral daily administration
that has shown promising properties as a potentially safe and effective RA
treatment.
Study GLPG0259-CL-201 is an exploratory Phase II study, where the safety and
tolerability and the preliminary efficacy of different doses of GLPG0259 will
be evaluated for the first time in patients with RA. PK assessments will be
also performed.
Study objective
Primary Objective:
To preliminarily evaluate the efficacy of GLPG0259 compared with placebo in
terms of the proportion of subjects achieving ACR20 at Week 12 (Visit [V]7).
Secondary Objectives:
•To evaluate the efficacy of GLPG0259 compared with placebo in terms of ACR
response criteria, time to response, and disease status (DAS28);
•To evaluate the safety and tolerability of GLPG0259 in comparison with placebo
in terms of AEs, laboratory test abnormalities, vital signs and ECGs; and
•To characterize the population pharmacokinetics of GLPG0259 and determine the
impact of covariates on PK parameter estimates of GLPG0259.
Study design
This will be an exploratory, Phase II, double-blind, placebo-controlled,
multicenter study in a maximum of 200 randomized subjects with active
rheumatoid arthritis (RA) who have an inadequate response to methotrexate. The
study consists of two parts:
Part A: Thirty eligible subjects will be randomized in a 2:1 allocation ratio
to a once-daily dose of 50 mg of GLPG0259 or placebo in addition to their
stable dose of methotrexate (20 subjects will receive GLPG0259 and 10 subjects
will receive placebo). During the course of treatment, the study drug dose may
be split (twice-daily dose of 25 mg each) or reduced to 25 mg/day based on the
individual subject*s drug tolerability. An interim analysis will be performed
at the end of Part A to assess the efficacy and tolerability of GLPG0259 versus
(vs) placebo. The number of subjects who required their dose to be
split/reduced in Part A will also be evaluated in order to determine the
highest dose (either 50mg/day or 25 mg/day) and dose regimen (either once or
twice daily) to be used in Part B. The number of subjects required to be
randomized to the highest dose selected will then be determined.
Part B: If the interim analysis at the end of Part A shows a clinical advantage
of GLPG0259 over placebo and the study progresses into Part B, depending on the
highest dose selected at least 150 additional subjects will either be
randomized to GLPG0259 50 mg/day, GLPG0259 25 mg/day, GLPG0259 12.5 mg/day, or
matching placebo; or to GLPG0259 25 mg/day, GLPG0259 12.5 mg/day, GLPG0259 6
mg/day, or matching placebo at the baseline visit.
At the end of the study, it is planned that 45 subjects will have been exposed
to the each of the three different doses of GLPG0259 or placebo.
Intervention
The investigational product will consist of two 25 mg capsules of GLPG0259 for
oral administration in Part A. All subjects will start Part A on a 50 mg/day
dose; the dose may subsequently be split so that one 25 mg capsule is taken
twice daily or, in the case of dose reduction, one 25 mg capsule will be taken
once daily.
In Part B, two capsules of 6.25, 12.5, and 25 mg (or 3, 6.25, and 12.5 mg
depending on the highest dose selected for Part B), will be taken either once
or twice daily for 12 weeks.
Depending on the outcome of Part A, final doses and dose regimens for Part B
may still be adapted.
Matching placebo capsules for oral administration will be taken for 12 weeks as
a reference
Study burden and risks
Thirty eligible subjects will be randomized in a 2:1 allocation ratio to a
once-daily dose of 50 mg of GLPG0259 or placebo in addition to their stable
dose of methotrexate (20 subjects will receive GLPG0259 and 10 subjects will
receive placebo). During the course of treatment, the study drug dose may be
split (twice-daily dose of 25 mg each) or reduced to 25 mg/day based on the
individual subject*s drug tolerability. An interim analysis will be performed
at the end of Part A to assess the efficacy and tolerability of GLPG0259 versus
(vs) placebo. The number of subjects who required their dose to be
split/reduced in Part A will also be evaluated in order to determine the
highest dose (either 50mg/day or 25 mg/day) and dose regimen (either once or
twice daily) to be used in Part B. The number of subjects required to be
randomized to the highest dose selected will then be determined.
Part B: If the interim analysis at the end of Part A shows a clinical advantage
of GLPG0259 over placebo and the study progresses into Part B, depending on the
highest dose selected at least 150 additional subjects will either be
randomized to GLPG0259 50 mg/day, GLPG0259 25 mg/day, GLPG0259 12.5 mg/day, or
matching placebo; or to GLPG0259 25 mg/day, GLPG0259 12.5 mg/day, GLPG0259 6
mg/day, or matching placebo at the baseline visit.
At the end of the study, it is planned that 45 subjects will have been exposed
to the each of the three different doses of GLPG0259 or placebo.
Please refer to question E4 and the flow chart on page 45 of the protocol for
all study procedures
Please refer to question E9 and the patient information for all possible risks
and adverse events
Gen. De Wittelaan L11 A3
2800 Mechelen
Belgie
Gen. De Wittelaan L11 A3
2800 Mechelen
Belgie
Listed location countries
Age
Inclusion criteria
1) 18-70 years of age on the day of signing informed consent
2) Fulfill the 1987 revised ACR criteria for the classification of RA, but must not be wheelchair or bed bound ( functional class IV)
3.Have active RA as shown by five or more swollen joints (from the 66-joint count), five or more tender joints (from 68-joint count), and a serum C-reactive protein (CRP) >=1.5 mg/dL;
4.Have received methotrexate for six months or longer and at a stable dose of 7.5 to 25 mg/week for >=12 weeks prior to screening and willing to continue on this regimen for the duration of the study;
5.If taking oral steroids, these should be at a dose <=10 mg/day of prednisone or prednisone equivalent and stable for at least four weeks prior to screening;
6.If taking non-steroidal anti-inflammatory drugs (NSAIDs), these must be at a stable dose for at least two weeks prior to screening;
7.The results of the following laboratory tests performed at the central laboratory at screening must be within the limits specified below:
a. Hemoglobin >=8.5 g/dL (International System of Units [SI]: >=85 g/L);
b. White blood cells >=3.0 x 103 cells/mm3 (SI: >=3.0 x109 cells/L);
c. Neutrophils >=1.5 x 103 cells/mm3 (SI: >=1.5 x109 cells/L);
d. Platelets >=100 x 103 cells/mm3 (SI: >=100 x109 cells/L);
e. Serum ALT and aspartate aminotransferase (AST) <=1.5 x ULN;
f. Total bilirubin level <=1.25 x ULN; and
8.Female subjects must have a negative pregnancy test unless they are surgically sterile or have been post-menopausal for at least one year (12 consecutive months without menses);
9.Women of childbearing potential must use a medically acceptable means of birth control and agree to continue its use during the study and for at least 12 weeks after the last dose of study drug. Women who have had a complete surgical hysterectomy or are postmenopausal are exempt from this requirement. Medically acceptable forms of birth control include oral contraceptives, injectable or implantable methods, intrauterine devices, tubal ligation (if performed more than one year before screening), or double barrier contraception. Sexually active men must agree to use a medically acceptable form of contraception during the study and continue its use for at least 12 weeks after the last dose of study drug; and
10.Able and willing to sign the informed consent prior to screening evaluations and agree to schedule of assessments.
Exclusion criteria
1. Treatment with DMARDs other than background methotrexate, including oral or injectable gold,sulfasalazine, hydroxychloroquine, azathioprine, or D penicillamine within four weeks prior to screening, cyclosporine within eight weeks prior to screening, and leflunomide within three months prior to screening;
2.Current or previous RA treatment with a biological agent, with the exception of biologics administered in a clinical study setting more than six months prior to screening (12 months for rituximab or other B cell depleting agents);
3.Previous treatment at any time with a cytotoxic agent, other than methotrexate, before screening. These agents include, but are not limited to, chlorambucil, cyclophosphamide, nitrogen mustard, or other alkylating agents;
4.Receipt of an intra-articular or parenteral corticosteroid injection within four weeks prior to screening;
5.Current regular use of aspirin or any other anti-coagulant medication;
6.Known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug as determined by the Investigator, such as anaphylaxis, requiring hospitalization;
7.Positive serology for human immunodeficiency virus (HIV)1 or 2 or hepatitis B or C, or any history of HIV or hepatitis from any cause with the exception of hepatitis A;
8.History of any inflammatory rheumatological disorders other than RA;
9.Have undergone surgical treatments for RA including synovectomy and arthroplasty within three months prior to screening and/or a joint surgery is planned within the next months;
10.Symptoms of clinically significant illness other than RA (including but not limited to cardiopulmonary, renal, metabolic, hematologic, or psychiatric disorders) within three months prior to screening;
11.History of active infections requiring intravenous antibiotics within the past four weeks;
12.History of malignancy within the past five years (except for basal cell carcinoma of the skin or carcinoma in situ of the cervix that has been treated with no evidence of recurrence);
13.History of tuberculosis (TB) infection as determined by:
a.a positive diagnostic TB test result (defined as a positive QuantiFERON TB Gold test), and
b.a chest radiograph (both posterior-anterior and lateral views), taken within three months prior to screening and read by a qualified radiologist, with evidence of current active TB or old inactive TB.
14.Administration of a live vaccine within four weeks prior to screening;
15.Participation in any investigational drug/device clinical study within four weeks prior to screening, in biological agents clinical studies within six months prior to screening, and B cell-depleting agent clinical studies within 12 months prior to screening;
16.History within the previous two years or current evidence of drug or alcohol abuse;
17.Pregnant or lactating women; and
18.Any condition or circumstances which in the opinion of the Investigator may make a subject unlikely or unable to complete the study or comply with study procedures and requirements, or may pose a risk to the subject*s safety.
Design
Recruitment
Medical products/devices used
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
EudraCT | EUCTR2009-015898-12-NL |
CCMO | NL32768.058.10 |